Table 2 Comparison between group of patients with normal overall Montreal score and those patients with abnormal score
From: Chemotherapy-induced cognitive impairment in hematological malignancies
Overall Montreal score | Chi-square | ||||||
|---|---|---|---|---|---|---|---|
Normal | Cognitive impairment | ||||||
N | % | N | % | χ 2 | p value | ||
Sex | Male | 40 | 70.18 | 57 | 61.29 | 1.22 | 0.26 |
Female | 17 | 29.82 | 36 | 38.71 | |||
Diagnosis | AML | 17 | 29.82 | 28 | 30.11 | 14.91 | 0.02 |
ALL | 8 | 14.04 | 7 | 7.53 | |||
CML | 11 | 19.30 | 5 | 5.38 | |||
CLL | 6 | 10.53 | 14 | 15.05 | |||
MDS | 0 | 0.00 | 2 | 2.15 | |||
Lymphoma | 4 | 7.02 | 21 | 22.58 | |||
Myeloma | 11 | 19.30 | 16 | 17.20 | |||
Chemotherapy | Intensified protocol | 23 | 40.35 | 33 | 35.48 | 5.76 | 0.12 |
TKIs | 8 | 14.04 | 5 | 5.38 | |||
Velcade | 11 | 19.30 | 16 | 17.20 | |||
Others | 15 | 26.32 | 39 | 41.94 | |||
Route of chemotherapy | Oral | 10 | 17.54 | 5 | 5.38 | 5.81 | 0.01 |
Parenteral | 47 | 82.46 | 88 | 94.62 | |||
Comorbidities | No | 53 | 92.98 | 51 | 54.84 | 26.52 | < 0.001 |
HTN | 0 | 0.00 | 16 | 17.20 | |||
DM | 2 | 3.51 | 8 | 8.60 | |||
Viral hepatic infection | 2 | 3.51 | 6 | 6.45 | |||
More than one | 0 | 0.00 | 12 | 12.90 | |||
Remission status | Remitted | 42 | 73.68 | 61 | 65.59 | 1.07 | 0.30 |
Resistant or refractory | 15 | 26.32 | 32 | 34.41 | |||